PTEN is a tumor suppressor gene which encodes a phosphatase that preferentially dephosphorylates phosphoinositide substrates and thereby modulates cell cycle progression and cell survival. PTEN is an important negative regulator of the PI3K/AKT/mTOR signaling pathway by dephosphorylating PIP3. PTEN is commonly mutated in human cancer, hence, loss of expression/function of PTEN due to mutations have been observed in prostate cancer, glioblastoma, endometrial, lung and breast cancers. Other non-cancerous clinical disorders associated with PTEN mutation are Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, and proteus-like syndrome. PTEN is phosphorylated at several residues and some lead to increase in activity while others lead to loss of function and degradation. Specifically, phosphorylation at serine 380 residue by casein kinase 2 (CK2), leads to degradation of PTEN in the proteasome.

PRODUCT DETAILS

Clone: A22005D

Antibody Type: Monoclonal

Reactivity: Human

Format: Alexa Fluor 488

Host: Mouse

Isotype: IgG1, κ

Applications: ICFC - Quality tested IHC-P - Verified

Regulatory Status: RUO

Data Sheets: TDS | SDS

Note to Purchaser: This product is manufactured and supplied by BioLegend, Inc. under an agreement between BioLegend, Inc. and Cytek Biosciences, Inc. Information related to this product is provided by BioLegend, Inc.